Novartis
PulseAugur coverage of Novartis — every cluster mentioning Novartis across labs, papers, and developer communities, ranked by signal.
5 day(s) with sentiment data
-
AI Hype Exposed: Big Pharma Loses Billions on Failed AI-Recommended Heart Drugs
Recent failures in Big Pharma drug development, where billions were invested in AI-recommended heart drugs, highlight the limitations of current AI large language models. Despite impressive speed and human-like response…
-
US FDA probes tumor risk in Novartis gene therapy Zolgensma
The U.S. Food and Drug Administration (FDA) is investigating potential tumor risks associated with Novartis' gene therapy, Zolgensma. This investigation follows reports of neoplasia, including malignancy, in children tr…
-
Cancer patient who inspired hit film seeks to end treatment after 2 decades
Lu Yong, a Chinese cancer patient whose life inspired the film "Dying to Survive," is reducing his medication after two decades of treatment. The film highlighted the struggles of patients seeking affordable drugs, lead…
-
AI to connect fragmented women's health data, says Novartis exec
Artificial intelligence holds significant potential to improve women's healthcare, particularly in addressing the fragmented approach to menopause symptoms. Currently, women often consult five to six different doctors w…
-
Biotech IPOs surge with over two dozen companies public this year
The biotech sector has seen a significant increase in companies going public this year, with over two dozen already having completed their IPOs. This trend is expected to continue, with more companies preparing to enter…
-
Bayer CEO restructures company, empowers teams to drive growth
Bayer CEO Bill Anderson has significantly restructured the company by reducing management layers and empowering small, agile teams to drive decision-making. Despite improving profitability and securing a key legal rulin…
-
New Spackle framework enhances single-image 3D reconstruction
Researchers have developed Spackle, a new framework designed to improve single-image novel view synthesis (NVS) by addressing the limitations of existing 3D Gaussian Splatting (3DGS) methods. Spackle uses a three-stage …
-
Anthropic's $2T IPO highlights unique trustee-controlled governance
Anthropic is preparing for a potential $2 trillion IPO, which is bringing its unique governance structure under intense public scrutiny. The company's Long-Term Benefit Trust (LTBT), composed of external advisors, holds…
-
AI giants pivot to health care to boost image and investor confidence · 1 source tracked
Major AI companies are increasingly focusing on health care applications to improve their public image and secure investor confidence. This strategic shift aims to counter negative perceptions surrounding AI's environme…
-
Novartis to Acquire UK Biotech Firm Myricx Bio for Up to $1.5 Billion
Novartis has agreed to acquire the UK-based cancer treatment company Myricx Bio for up to $1.5 billion. This acquisition represents the latest in a series of foreign investments into the UK's biotechnology sector. The d…
-
Google DeepMind spinoff Isomorphic Labs advances AI drug discovery
Isomorphic Labs, a Google DeepMind spinoff, is advancing AI-driven drug discovery by developing new computational systems. Their Isomorphic Drug Design Engine (IsoDDE) builds upon AlphaFold's protein structure predictio…
-
SpaceX eyes healthcare with Starlink, orbital drug manufacturing, and AI
SpaceX is exploring multiple avenues into the healthcare sector, leveraging its Starlink satellite internet service to improve remote healthcare access in underserved regions. The company also plans to manufacture pharm…
-
Sanofi builds internal AI ecosystem, eschewing third-party tools
Sanofi is developing its own AI ecosystem, moving away from licensing third-party tools like ChatGPT and Copilot. The company has launched an internal generative AI assistant called Concierge, now used by 80% of its wor…
-
Demis Hassabis' Isomorphic Labs raises $2.1B for AI drug discovery
Isomorphic Labs, an AI drug discovery startup founded by Demis Hassabis, has secured $2.1 billion in Series B funding led by Thrive Capital. The company plans to use the new capital to scale its compute resources, gener…
-
Kordata Dynamics launches neurotech platform for clinical trials
Kordata Dynamics has launched to address a $26 billion market in central nervous system (CNS) therapeutics by integrating neurotechnology into clinical trials. The company, a spinout from BIOS Health, will partner with …
-
Anthropic adds Novartis CEO Vas Narasimhan to Board of Directors
Anthropic's Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of Novartis, to its Board of Directors. Narasimhan's extensive experience in developing and approving new medicines in a highly regulated industry is…
-
Google DeepMind spinoff Isomorphic Labs raises $2.1B for AI drug trials
Isomorphic Labs, an AI-driven drug discovery company spun out of Google DeepMind, has secured over $2 billion in a Series B funding round. The substantial investment, led by Thrive Capital, will be used to expand its pr…